AzTrials
AzTrials

GeneticsNCT02566161

Parental Irradiation of Ukrainian Cleanup Workers and Evacuees and Germline Mutations in Their Offspring (Trio Study)

An observational study of Genetics, run by National Cancer Institute (NCI) at 1 site in Ukraine.

Terminated

Stopped early. The study ended before it was planned to and will not resume.

Official record
Search all trials

Trial summary

Data on transgenerational effects following nuclear accidents are important for understanding fully the consequences of parental exposure to ionizing radiation. Few studies to date have had adequate statistical power to detect effects of the magnitude expected based on animal data, and most have not been of low-dose… Read more about this study

Who is it for?
Ages 18 to 70 yearsHealthy volunteers can take part
Conditions the study is for
Genetics
How many people
957 participants
Where
1 siteUkraine
Study dates
1 Oct 2015to 10 Jul 2020
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 70 years
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Study population: The Clinical-Epidemiological Registry (CER) of the RCRM will serve as the fundamental information source for the identification of potential trio subjects. The CER was established in 1992 for long-term extended active follow-up of representative populations exposed to ionizing radiation due to the Chernobyl nuclear power plant (ChNPP)accident, drawn from those listed in the State Chernobyl Registry. The study will include all parent-offspring trios/quartets selected from the group of approximately 450 trios with offspring born 42 or more weeks after the last significant parental Chernobyl-related exposure.

Who may be able to join

  • all parent-offspring trios/quartets selected from the group of approximately 450 trios with offspring born 42 or more weeks after the last significant parental Chernobyl-related exposure. ---The offspring can be of either sex
  • Must be an adult
  • (age (Bullet) 18 years at interview);
  • If more than one child is born to a given set of parents, the first and last such eligible siblings will be selected for participation, in the interests of maximizing the variation of time from last exposure to conception, also to maximize the signal (by including offspring closest in time to the exposure, with less likelihood of removal of damaged sperm/oocytes, and by including offspring furthest in time from the exposure, with less likelihood of direct exposure of the child, and maximizing cumulative parental preconception gonadal dose).
  • Twins will be especially informative given the comparable exposures in utero and in early life. A high proportion of the trios/quartets currently reside in Kyiv. The majority of these trios/quartets have undergone regular medical examinations as a result of follow-up by the CER. Most of them are expected to be alive.

Who cannot join

  • Those who cannot be located
  • Those with offspring born within 42 weeks of the last significant Chernobyl-related exposure
  • Those parents or offspring found to have cancer
  • Those who refuse to participate in the study, or who do not provide informed consent.

Trial locations and contacts

1 site in 1 country.

Ukraine1 site
  • Research Center for Radiation Medicine

    Kiev

Other trials in Ukraine

About this study

Data on transgenerational effects following nuclear accidents are important for understanding fully the consequences of parental exposure to ionizing radiation. Few studies to date have had adequate statistical power to detect effects of the magnitude expected based on animal data, and most have not been of low-dose, protracted exposures associated with nuclear accidents and their aftermath. Although, to date, scant use has been made of the new genomic technologies, in Chernobyl-exposed areas of Ukraine and Belarus, excess minisatellite mutations have been seen in children born after the accident. We propose a study of parent-child trios in which at least one parent was exposed to Chernobyl radiation as a clean-up worker (mean dose >=100 mGy) and/or evacuee from a contaminated area (mean >= 50mGy). The specific aims are to investigate the transgenerational and de novo mutation rates of the spectrum of genetic variants in trios, in particular looking at effects in children and mapping them to possible parental origin of the chromsome. Together with long-term collaborators at the Research Center for Radiation Medicine (RCRM) in Kiev, epidemiologic data will be collected for up to 450 trios of parents with preconceptional doses and their unexposed offspring. We will use state-of-the-art genomic technologies to characterize the landscape of the genomes of the trios to determine whether parental radiation exposure is associated with genetic mutations transmitted to the offspring, by examining de novo mutation rates, minisatellite mutations, copy number alterations, and variations in telomere length. The analysis will be conducted in peripheral blood and/or buccal samples (when blood is not available) from complete father-mother-child trios. Doses to the gonads from the time of the accident to the time of conception will be reconstructed for all parents using existing records supplemented by interview data.

Trio subjects will be selected from representative populations exposed to radiation from Chernobyl who are under active follow-up in the Clinico-Epidemiologic Registry at RCRM. To help identify specific effects of paternal and maternal radiation exposure, we will initially select sets of trio subjects in five categories: (1) exposed father, unexposed mother; (2) unexposed father, exposed mother; (3) both parents exposed; (4) both parents unexposed; and (5) a group of high dose emergency workers with acute radiation syndrome. All trio members will be invited to the RCRM outpatient clinic for collection of a 20 ml blood sample (or buccal cells for those who refuse phlebotomy). Both parents will be asked to complete a general questionnaire to obtain demographic and lifestyle data. Then one or both will complete detailed dosimetry questionnaires, based on forms used in previous collaborations with RCRM and administered by specially trained interviewers. Once 50 trios have been recruited (10 from each of the 5 exposure categories), we will conduct an interim evaluation of participation rates, sample collection and quality, and dose reconstruction in order to modify the protocol as needed. The analytical approach will be to correlate the extent, especially for de novo events of genetic alterations in the offspring with parental preconceptional radiation dose overall and by parental origin. The statistical power in relation to de novo mutations is very high, in excess of 90%, but somewhat lower for trends in minisatellite mutations. Study findings will contribute importantly to knowledge of the heritable effects of moderate- and low-dose radiation exposure in humans and to radiation risk projection. Eventually data from the Trio Study may be shared with the international community through dbGap.

Read the detailed description

Data on transgenerational effects following nuclear accidents are important for understanding fully the consequences of parental exposure to ionizing radiation. Few studies to date have had adequate statistical power to detect effects of the magnitude expected based on animal data, and most have not been of low-dose, protracted exposures associated with nuclear accidents and their aftermath. Although, to date, scant use has been made of the new genomic technologies, in Chernobyl-exposed areas of Ukraine and Belarus, excess minisatellite mutations have been seen in children born after the accident. We propose a study of parent-child trios in which at least one parent was exposed to Chernobyl radiation as a clean-up worker (mean dose >=100 mGy) and/or evacuee from a contaminated area (mean >= 50mGy). The specific aims are to investigate the transgenerational and de novo mutation rates of the spectrum of genetic variants in trios, in particular looking at effects in children and mapping them to possible parental origin of the chromsome. Together with long-term collaborators at the Research Center for Radiation Medicine (RCRM) in Kiev, epidemiologic data will be collected for up to 450 trios of parents with preconceptional doses and their unexposed offspring. We will use state-of-the-art genomic technologies to characterize the landscape of the genomes of the trios to determine whether parental radiation exposure is associated with genetic mutations transmitted to the offspring, by examining de novo mutation rates, minisatellite mutations, copy number alterations, and variations in telomere length. The analysis will be conducted in peripheral blood and/or buccal samples (when blood is not available) from complete father-mother-child trios. Doses to the gonads from the time of the accident to the time of conception will be reconstructed for all parents using existing records supplemented by interview data.

Trio subjects will be selected from representative populations exposed to radiation from Chernobyl who are under active follow-up in the Clinico-Epidemiologic Registry at RCRM. To help identify specific effects of paternal and maternal radiation exposure, we will initially select sets of trio subjects in five categories: (1) exposed father, unexposed mother; (2) unexposed father, exposed mother; (3) both parents exposed; (4) both parents unexposed; and (5) a group of high dose emergency workers with acute radiation syndrome. All trio members will be invited to the RCRM outpatient clinic for collection of a 20 ml blood sample (or buccal cells for those who refuse phlebotomy). Both parents will be asked to complete a general questionnaire to obtain demographic and lifestyle data. Then one or both will complete detailed dosimetry questionnaires, based on forms used in previous collaborations with RCRM and administered by specially trained interviewers. Once 50 trios have been recruited (10 from each of the 5 exposure categories), we will conduct an interim evaluation of participation rates, sample collection and quality, and dose reconstruction in order to modify the protocol as needed. The analytical approach will be to correlate the extent, especially for de novo events of genetic alterations in the offspring with parental preconceptional radiation dose overall and by parental origin. The statistical power in relation to de novo mutations is very high, in excess of 90%, but somewhat lower for trends in minisatellite mutations. Study findings will contribute importantly to knowledge of the heritable effects of moderate- and low-dose radiation exposure in humans and to radiation risk projection. Eventually data from the Trio Study may be shared with the international community through dbGap.

Conditions
Genetics
Keywords
Genetics, Genomics

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT02566161
Study groupRoleWhat they receive
Trio Cohortfamilies were from each of 5 exposure categories: A-father exposed, mother unexposed; B-mother exposed, father unexposed; C-both parents exposed; D-neither exposed; E-high dose emergency workers).

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. The primary objective of this study is to investigate the association of parental preconceptual gonadal dose with genetic alterations in the offspring.

    Inherited genetic mutations

    Measured: following sample collection

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted2 Oct 2015 (estimated)
  2. Study start1 Oct 2015
  3. Primary completion10 Jul 2020
  4. Study completion10 Jul 2020

Why it stopped: protocol qualifies as not human subjects research

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Family based
Time perspective
Cross-sectional
Enrolment
957 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02566161
Sponsor's protocol ID
999915199
Other IDs
15-C-N199
Status last verified
Jul 2020
First submitted
1 Oct 2015
Last updated
12 Mar 2021
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No

Publications

  • Little MP, Goodhead DT, Bridges BA, Bouffler SD. Evidence relevant to untargeted and transgenerational effects in the offspring of irradiated parents. Mutat Res. 2013 Jul-Sep;753(1):50-67. doi: 10.1016/j.mrrev.2013.04.001. Epub 2013 May 4.

    PubMed 23648355
  • Dubrova YE, Grant G, Chumak AA, Stezhka VA, Karakasian AN. Elevated minisatellite mutation rate in the post-chernobyl families from ukraine. Am J Hum Genet. 2002 Oct;71(4):801-9. doi: 10.1086/342729. Epub 2002 Sep 11.

    PubMed 12226793
  • Bouffler SD, Bridges BA, Cooper DN, Dubrova Y, McMillan TJ, Thacker J, Wright EG, Waters R. Assessing radiation-associated mutational risk to the germline: repetitive DNA sequences as mutational targets and biomarkers. Radiat Res. 2006 Mar;165(3):249-68. doi: 10.1667/rr3506.1.

    PubMed 16494513

Questions about this trial

What is this clinical trial studying?

An observational study of Genetics, run by National Cancer Institute (NCI) at 1 site in Ukraine.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: stopped early, as of the sponsor's last update on 12 Mar 2021. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Ukraine. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study was stopped early (reason given: protocol qualifies as not human subjects research). Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

The primary objective of this study is to investigate the association of parental preconceptual gonadal dose with genetic alterations in the offspring. (time frame: following sample collection). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02566161, which also lists 3 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Mar 2021.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in